Background {#Sec1}
==========

Metastases from extramammary malignant neoplasms are very rare, since they account for less than 2 % of all breast malignancies \[[@CR1]\]. In general, symptoms are similar in those of primary mammary carcinoma, including palpable relatively well-circumscribed and freely movable masses within the breast, pain, tenderness, and inflammation. Non primary breast malignancies are generally well defined and rounded, and calcification is unusual. On mammography, these lesions can be mistaken for benign (fibroadenoma) as well as primary breast malignancies \[[@CR1], [@CR2]\].

Metastasis from many extramammary neoplasms have been described, such as lymphomas, malignant melanoma, carcinomas of the lung, ovary, prostate, kidney, stomach, small bowel, large bowel, thyroid, cervix, and soft tissues \[[@CR1], [@CR3]--[@CR8]\].

Distinction of metastases to the breast from extramammary neoplasms from primary breast neoplasms is important for determining the best management. In patients with metastatic disease, a systemic and palliative approach is usually more effective. Moreover, correct diagnosis may prevent unnecessary surgery. The aim of this study is to report the incidence of lymphomas and metastases to the breast of extramammary malignancies in our 30-year archive.

Methods {#Sec2}
=======

The pathology database of a single institute was used to identify all breast neoplasms which were coded in our system as a *metastasis* in the period of 30 years (1985--2014). Each case was retrospectively reviewed by an experienced pathologist in order to determine whether or not the malignancy was rightly coded as non primary breast malignancy. We also included secondary metastases from leukemia-lymphomas to the breast. For all patients, histological reports were reviewed to determine the primary site of the tumor. We reviewed the first manifestation of the primary tumor. Patients with metastatic tumors from primary (contralateral) breast carcinoma were excluded. Additional data were obtained from the hospital electronic record system, retrospectively.

Results {#Sec3}
=======

In the study period, approximately 9000 breast cancers were diagnosed in our laboratory. Fifty-nine of these patients with breast neoplasms were coded as a *metastasis*. In total, 12 patients were excluded because of the following reasons: six were coded incorrectly, they were diagnosed with primary breast cancer, three were excluded because of incomplete information, one was diagnosed with a metastatic tumor from primary breast carcinoma, and two were skin tumors involving the breast, respectively, one squamous cell carcinoma and one primary T cell lymphoma. The final study group comprised 47 patients (Table [1](#Tab1){ref-type="table"}). Females were more frequently affected (7 men, 40 women). The mean age was 63 years (range 32--87). The metastases appeared on average after 39 months (range 1--273) after diagnosis of primary extramammary malignancy. In 24 of the 44 patients (51 %), the metastasis was the first sign of the specific malignant disease.Table 1Patients characteristicsAge, yearsYears Mean 63 Range 32--87SexNumber of patients (%) Men 7 (15) Women 40 (85)Time interval diagnosis: primary neoplasm metastasis (incl. lymphomas)Months Mean 39 Range 1--273Known malignant disease (incl. lymphomas)Number of patients (%) No history of primary malignant disease 24 (51 %) History of primary malignant disease 23 (49 %)

The histology of extramammary breast neoplasms is shown in Table [2](#Tab2){ref-type="table"}. The most common primary neoplasm was lymphoma, followed by melanoma. Other primary tumor sites included the ovary, lung, colon, kidney, stomach, and the chorion. In three patients with melanoma (27 % \[3/11\]), no primary site was found, most probably due to complete regression of a skin melanoma. All 18 mammary lymphomas were B cell type lymphomas (13 primary, 5 secondary).Table 2Histology of breast metastasesPrimary histologyNumber of patients (%)Interval (months): primary-secondary (mean)Lymphoma18 (38.3 %) Primary13 Secondary55--64 (24)Melanoma11 (23.4 %) No primary site3 Primary side detected84--273 (66)Ovarian carcinoma6 (12.8 %) No history of ovarian carcinoma1 History of ovarian carcinoma51--43 (15)Lung carcinoma6 (12.8 %) No history of lung carcinoma4 History of lung carcinoma210--28 (19)Adenocarcinoma of the colon3 (6.4 %) No history of colon carcinoma1 History of colon carcinoma21--5 (3)Renal cell carcinoma1 (2.1 %) No history of renal cell carcinoma0 History of renal cell carcinoma12 (−)Adenocarcinoma of the stomach1 (2.1 %) No history of stomach carcinoma1 History of stomach carcinoma0--Choriocarcinoma1 (2.1 %) No history of choriocarcinoma 1 History of choriocarcinoma 0--Total47 (100 %)

The diagnosis in our group of 47 patients was obtained by core biopsy or with fine-needle aspiration (Table [3](#Tab3){ref-type="table"}). In total, core biopsy was performed in 32 patients (68 %), 14 patients (30 %) had a fine-needle aspiration, and one patient (2 %) was operated without preoperative diagnostics; in this case, an intra-operative frozen section was performed. Seven patients (15 %) had breast surgery. All underwent modified radical mastectomy; the postoperative pathology revealed three melanomas, two ovarian carcinomas, one lymphoma, and one adenocarcinoma of the colon. In these patients, the diagnosis was obtained by core biopsy in three; in two of them, the preoperative diagnosis of primary breast cancer was incorrect retrospectively (i.e., primary breast carcinoma). The remaining patient had a correct preoperative diagnosis, and the surgery was performed for palliation, i.e., local control. Three patients had breast surgery after diagnosis obtained by fine-needle aspiration; in one, there was an incorrect preoperative diagnosis (i.e., primary breast carcinoma), and two patients underwent palliative surgical resection. One patient had no preoperative pathological diagnosis; however, the intra-operative frozen section revealed breast carcinoma, and after postoperative analyses, this diagnosis was adjusted with ovarian carcinoma.Table 3Type of diagnostics and surgeryTypeNumber (%)Surgery (*n*)Final diagnosis after surgeryCore biopsy32 (68)3- Lymphoma (*n* = 1)\
- Melanoma (*n* = 1)\
- Ovarian carcinoma (*n* = 1): palliative resection^a^Fine needle aspiration14 (30)3- Melanoma (*n* = 2): palliative resection^a^\
- Colon carcinoma (*n* = 1)Frozen section1 (2)1- Ovarian carcinoma (*n* = 1)Total (*n*)47 (100)7^a^Correct preoperative diagnosis

Discussion {#Sec4}
==========

Breast metastases of extramammary neoplasms are extremely rare. In our laboratory, we found a total of 47 patients with metastases to the breast from non mammary primary in a 30-year period, representing an incidence of approximately 0.5 %. In our study, lymphomas and melanomas were the most prevalent primary neoplasms (38 and 23 %, respectively), which is in accordance with previous reported studies \[[@CR1], [@CR2], [@CR4], [@CR9]\]. Lee et al. reported gastric cancers to be the most common metastases to the breast. However, gastric carcinoma is the most common form of cancer in Korea and the incidence of melanoma is much lower \[[@CR10]\].

In our study, patients with breast metastases presented with a mean of 39 months after diagnoses of primary cancer. Patients with primary melanomas presented with the largest time interval between primary presentation and breast metastases with a mean of 66 months, probably reflecting the well-known natural history of melanoma with a subgroup showing late recurrence. Lee et al. reported a mean time interval of 14 months, but this difference in interval might be explained by the larger amount of melanomas included in our study (23 vs 6 %) \[[@CR10]\].

In this study, in four patients (9 %), the diagnosis had to be corrected postoperatively. This percentage seems poor; however, it should be considered that diagnosis of extramammary metastasis to the breast is difficult not only because clinical presentation may be similar to primary breast malignancies but also because it may be the first presentation of unknown metastatic disease. In addition, the diagnosis is hard to make on cytology alone. Obviously, proper clinical information may be helpful and should be provided to the pathologist at all times.

Histological diagnosis is important to distinguish metastases to the breast from common primary breast carcinoma for effective treatment and direct attention to the extramammary primary, and in case of metastases to the breast prevent unnecessary surgery. Lee et al. reviewed histological and immunohistochemical features that are useful in the diagnosis of metastases to the breast. They discovered that about a third of the lesions do not show specific histological features. Elastosis and carcinoma in situ are common histological characteristics in primary mammary cancers. Different types of carcinoma are suggestive for specific origins, such as clear cell carcinoma for renal origin, small cell carcinoma of pulmonary origin, and papillary carcinoma of ovarian serous papillary carcinoma. For malignant melanomas, the appearance of cytoplasmic pigment, intranuclear inclusions, and spindle cells may be useful clues \[[@CR11]\].

Immunohistochemical panels can be of great value when trying to distinguish mammary carcinoma from common metastases to the breast. A mammary origin can be supported by the expression of estrogen receptor, progesterone receptor, her2neu, and GCDFP-15. Recently, GATA-3 has been shown to be a sensitive marker for breast cancer \[[@CR12], [@CR13]\]. However, these markers are not entirely specific, e.g., estrogen receptor can be expressed in ovarian cancer and GATA-3 is also a sensitive marker for urothelial cancer. Sensitive markers for the metastases that we found in our series are summarized in Table [4](#Tab4){ref-type="table"} \[[@CR14], [@CR15]\]. These markers should always be used in a panel of antibodies since no single marker is completely sensitive or specific. These markers are readily available on core biopsies but can also be applied to cytological specimens.Table 4Sensitive markers for specific metastases, these markers are negative in breast cancerPrimary originMarkerLung adenocarcinomaTTF-1Lung small cell carcinomaTTF-1, CD56MelanomaHMB45, Melan-AOvarian cancerPax-8, WT1, Ca 125Colorectal carcinomaCDX2, CK20Malignant B cell lymphomaCD20, CD79aRenal cell carcinomaPax-5, RCCChoriocarcinomaHCG-beta

Several authors emphasized the usages of fine-needle cytology \[[@CR16]--[@CR19]\]. Fulciniti et al. emphasized the usage of cytopathological criteria in combination with immunocytochemistry when considering the diagnosis of metastases to the breast \[[@CR16]\]. As stated before, diagnosis of metastases to the breast of non primary breast malignancies should be performed by a combination of clinical presentation and evaluation of the pathology and specific antibodies.

Conclusions {#Sec5}
===========

It is concluded that although metastases to the breast are rare, it should be considered in the differential diagnosis of breast cancer if the morphology is unusual for primary breast malignancies and if there is a history of a prior (treated) malignancy, in order to avoid unnecessary surgery.
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